Content matching 'embryonic stem cells'
Logical process designs for stem cell manufacturing: computational support tools for improved cost-effectiveness
Ahead of print foreword from Regenerative Medicine (Volume 10 Issue 03), a special focus on immunity in regenerative medicine, scheduled to be published in April
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative than drugs, and hence more valuable. That's the way Alain Vertès of NxR Biotechnologies sees it. In this interview with The Life Sciences Report, Vertès talks about some of the stem cell names he knows well, and draws comparisons investors can bank on.
Latest developments compiled from 1 July until 31 August 2014